Hims & Hers Health (HIMS) AI Stock Analysis

• Market Cap: $12.25B
• Dividend Yield: N/A
• Average Volume (3M): 51.85M
• Price to Earnings (P/E): 78.0
• Beta (1Y): 3.00
• Revenue Growth: 85.99%
• EPS Growth: N/A
• Country: US
• Employees: 1,637
• Sector: Healthcare
• Sector Strength: 41
• Industry: Household & Personal Products
• EPS (TTM): 0.20
• Shares Outstanding: 215,453,900
• 10 Day Avg. Volume: 36,643,650
• 30 Day Avg. Volume: 51,845,719
• PEG Ratio: 2.61
• Price to Book (P/B): 22.86
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 50.73
• Enterprise Value/Market Cap: 0.98
• Enterprise Value/Revenue: 2.15
• Enterprise Value/Gross Profit: 8.71
• Enterprise Value/Ebitda: 41.08
• 1Y Price Target: $42.09
• Price Target Upside: -21.49% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 11

• Rating: 77 Outperform
• Price Target: $61.00 ▲(13.78%Upside)

The overall score reflects strong financial performance and positive earnings call highlights, tempered by high valuation concerns and potential volatility risks. Long-term strategic guidance and planned expansions provide optimism.

Positive Factors

Strategic Expansion

HIMS' acquisition of ZAVA marks a significant strategic expansion for the company as it materially increases its international footprint.

User Base Growth

Through the acquisition, HIMS anticipates its active user base will grow by 50% as the company expands into Ireland, France, and Germany.

Negative Factors

Execution Risk

There is some execution and integration risk associated with the deal.

International Expansion Risks

Expanding internationally while the US business slows is a risk and may reflect product saturation and rising competition in the U.S. markets.

Hims & Hers Health Business Overview & Revenue Model

Company Description

Hims & Hers Health (HIMS) is a telehealth company that operates in the healthcare and wellness sectors. The company provides a digital platform offering a range of health and wellness services, including prescription and over-the-counter medication, personal care products, and access to licensed healthcare professionals. Their services target common conditions such as hair loss, sexual health, skin care, and mental health, providing consumers with convenient and affordable healthcare solutions.

How the Company Makes Money

Hims & Hers Health generates revenue primarily through the sale of its products and services via its online platform. The company's business model includes a direct-to-consumer approach, where customers can subscribe to monthly plans for recurring shipments of prescription medications and personal care products. Revenue streams are diversified across various health categories, including sexual health, dermatology, mental health, and primary care. Key factors contributing to its earnings include its ability to leverage telemedicine to reduce costs and improve accessibility, its subscription-based model that ensures recurring revenue, and strategic partnerships with healthcare professionals and pharmaceutical companies to broaden its service offerings.

Hims & Hers Health Financial Statement Overview

Summary

Hims & Hers Health exhibits strong revenue growth and improved profitability metrics, supported by a solid balance sheet with low leverage and increasing equity. The company has effectively managed cash flows, ensuring positive free cash flow generation. While historical challenges such as negative earnings and equity should be considered, the current financial trajectory is positive, indicating a stable outlook in the Household & Personal Products industry.

Income Statement

Hims & Hers Health has demonstrated robust revenue growth and improving profitability. Over the TTM, total revenue increased significantly by 20.86% from the previous annual period. The company's gross profit margin stood at 74.73%, and the net profit margin improved to 9.21%. Additionally, the EBIT margin increased to 6.19%, indicating better operational efficiency. However, historical losses and fluctuating margins in previous years pose a potential risk.

Balance Sheet

The balance sheet shows a healthy equity position with an equity ratio of 61.58%, indicating strong financial stability. The debt-to-equity ratio is low at 0.12, reflecting conservative leverage. Return on equity improved to 29.92%, suggesting effective use of equity to generate profits. The increase in stockholders' equity over time highlights the company's capital strength. However, past negative equity and liabilities exceeding assets in earlier years should be noted.

Cash Flow

Hims & Hers Health's cash flow from operations has consistently improved, with a significant increase in free cash flow by 14.68% over the latest period. The operating cash flow to net income ratio is robust at 2.03, demonstrating strong cash generation relative to earnings. The company has maintained positive free cash flow, indicative of good cash management practices. Past periods of negative free cash flow and operational cash flow constraints may pose risks.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.78B	1.48B	872.00M	526.92M	271.88M	148.76M
	Gross Profit
1.37B	1.17B	714.95M	408.72M	204.49M	109.45M
	EBIT
109.90M	61.90M	-29.45M	-68.70M	-115.04M	-15.14M
	EBITDA
132.26M	78.99M	-19.94M	-61.22M	-110.97M	-14.09M
	Net Income Common Stockholders
164.40M	126.04M	-23.55M	-65.68M	-107.66M	-18.11M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
203.59M	300.25M	220.98M	179.63M	247.27M	100.21M
	Total Assets
448.11M	707.54M	441.19M	366.34M	420.58M	118.70M
	Total Debt
11.82M	11.35M	9.95M	5.31M	5.48M	0.00
	Net Debt
-93.41M	-209.24M	-86.72M	-41.47M	-66.30M	-27.34M
	Total Liabilities
103.62M	230.82M	97.16M	54.60M	85.97M	265.57M
	Stockholders Equity
344.48M	476.72M	344.03M	311.74M	334.62M	-146.87M
Cash Flow		Free Cash Flow
240.22M	209.43M	46.99M	-33.78M	-39.42M	-6.71M
	Operating Cash Flow
334.34M	251.08M	73.48M	-26.53M	-34.41M	-2.48M
	Investing Cash Flow
-64.89M	-19.05M	-12.11M	34.70M	-156.27M	-39.70M
	Financing Cash Flow
-100.56M	-107.84M	-11.47M	-33.13M	235.04M	47.74M

Hims & Hers Health Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 53.61
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HIMS, the sentiment is Neutral. The current price of 53.61 is below the 20-day moving average (MA) of 56.52, above the 50-day MA of 41.43, and above the 200-day MA of 31.20, indicating a neutral trend. The MACD of 3.16 indicates Positive momentum. The RSI at 53.00 is Neutral, neither overbought nor oversold. The STOCH value of 15.09 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HIMS.

Hims & Hers Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IPAR	80 Outperform	$4.39B	26.58	22.16%	2.22%	10.32%	18.55%
HIMS	77 Outperform	$12.25B	78.03	36.79%	―	85.99%	―
EPC	69 Neutral	$1.25B	15.48	5.53%	2.26%	-2.11%	-28.79%
ELF	67 Neutral	$6.47B	61.05	15.97%	―	46.27%	-26.45%
COTY	60 Neutral	$4.34B	40.12	-10.58%	―	-1.68%	-302.11%
NUS	54 Neutral	$389.37M	―	-4.93%	3.04%	-11.85%	-1080.00%
Sector *	53 Neutral	$5.25B	3.24	-45.38%	2.81%	16.79%	-0.06%

Hims & Hers Health Corporate Events

Hims & Hers Health Issues $1 Billion in Notes

On May 13, 2025, Hims & Hers Health issued $1 billion in senior unsecured notes, which are equal in payment rights to the company’s existing and future senior unsecured debts but are subordinate to secured debts. These notes, maturing on May 15, 2030, offer conversion options into Class A common stock under specific conditions and include provisions for redemption and repurchase under certain corporate events. Additionally, the company engaged in capped call transactions to mitigate potential stock dilution from note conversions, with a cap price set at $89.95 per share, representing a 75% premium over the stock’s last reported sale price on May 8, 2025.

The most recent analyst rating on (HIMS) stock is a Hold with a $40.00 price target. To see the full list of analyst forecasts on Hims & Hers Health stock, see the HIMS Stock Forecast page.

Hims & Hers Announces $450M Convertible Notes Offering

On May 8, 2025, Hims & Hers Health, Inc. announced a proposed private offering of $450 million in Convertible Senior Notes due 2030, aimed at qualified institutional buyers. The proceeds from this offering are intended to support the company’s global expansion and investment in AI and personalized healthcare solutions, reflecting Hims & Hers’ strategic focus on scaling access to high-quality, personalized care. The offering is expected to enhance the company’s market positioning by funding organic growth and potential acquisitions, although no definitive acquisition agreements are in place at this time.

Hims & Hers Health COO Transition to Advisory Role

On April 21, 2025, Melissa Baird, the Chief Operating Officer of Hims & Hers Health, announced her plan to transition into an advisory role with the company. Her departure date is yet to be determined, but she will remain until a successor is found to ensure a smooth transition, and a long-term agreement will be established to retain her expertise.